• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

FDA gives clearance for skin resurfacing device

A fractional nonablative laser module, the ResurFX for the Lumenis M22 platform, has been given 510(k) clearance from the Food and Drug Administration.

 

 

A fractional nonablative laser module, the ResurFX for the Lumenis M22 platform, has been given 510(k) clearance from the Food and Drug Administration.

The ResurFX module has a 1,565 nm fiber laser and CoolScan scanner to allow homogeneous and uniform patterns of coagulation columns, according to a news release. CoolScan allows clinicians to choose as many as 600 combinations of shapes, sizes and densities. The scanner allows for tissue to “relax” between pulses and protects the skin from overheating.

“The ResurFX module with the CoolScan scanner allows me to treat patients faster and with greater efficacy, without having to compromise on patient comfort and safety,” Mitchel P. Goldman, M.D., volunteer clinical professor of dermatology, University of California, San Diego, said in the statement.

To get weekly news and analysis for today's skincare specialists, subscribe to Dermatology Times eNews.

 

Related Videos
3 experts are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
3 experts in this video
3 experts in this video
© 2024 MJH Life Sciences

All rights reserved.